Follistatin 344

<p><strong>Follistatin-344</strong> is the predominant naturally occurring isoform of follistatin, a single-chain monomeric glycoprotein of 344 amino acids that acts as a high-affinity binding protein and systemic neutralizer for activin A, activin B, and multiple bone morphogenetic proteins (BMPs). Follistatin functions by binding these TGF-beta superfamily ligands with 1:2 (follistatin:ligand) stoichiometry, preventing receptor engagement and downstream Smad2/3 or Smad1/5/8 pathway activation. It is most recognized in the research literature for its role as a potent negative regulator of myostatin (GDF-8) and activin A, both of which suppress skeletal muscle mass in a dose-dependent manner. Pharmacological follistatin neutralizes these inhibitory signals, producing muscle fiber hypertrophy in animal models.</p>

<h2>Mechanism of Action</h2>

<h3>Myostatin and Activin A Neutralization</h3>

<p>Myostatin (GDF-8) and activin A are the two most studied follistatin targets in skeletal muscle biology. Both signal through ActRIIB (activin receptor type IIB) on muscle cells, activating Smad2/3 phosphorylation and downstream inhibition of protein synthesis and satellite cell proliferation. Follistatin-344 binds both ligands with sub-nanomolar affinity, forming stable non-signaling complexes that reduce their bioavailability at the receptor. Lee and colleagues (PMID 11792847) demonstrated in a landmark study that follistatin overexpression in mice produced approximately 200-300% increases in muscle mass — roughly double the effect of myostatin knockout alone — consistent with follistatin neutralizing additional ligands beyond myostatin (specifically activin A and GDF-11) that also suppress muscle growth via ActRIIB.</p>

<h3>BMP Pathway Modulation</h3>

<p>Beyond muscle, follistatin-344 binds and neutralizes BMP-2, BMP-4, BMP-7, and other BMPs, producing effects on bone formation, adipogenesis, folliculogenesis, and neural differentiation. The affinity of follistatin for different BMPs varies significantly, and the heparin-binding domain of follistatin-344 allows it to localize to cell surfaces and extracellular matrix, modulating BMP availability in a spatially restricted manner. This localization property differentiates follistatin-344 from the shorter isoform follistatin-288, which lacks the C-terminal domain and shows different tissue distribution and heparin-binding behavior.</p>

<h3>Follistatin-344 vs. Follistatin-288</h3>

<p>The -344 isoform retains a 27-amino-acid C-terminal extension absent from follistatin-288 (produced by alternative mRNA splicing). This extension contains heparin-binding residues that cause follistatin-344 to be retained in the extracellular matrix and on cell surfaces, producing localized pericellular activity. Follistatin-288 is more freely circulating. In ovarian and reproductive research contexts, these two isoforms have distinct physiological roles, and the choice of isoform matters for experimental interpretation.</p>

<h2>Research Applications</h2>

<ul> <li><strong>Skeletal muscle hypertrophy and atrophy research</strong> — muscle mass regulation in animal models of sarcopenia, cachexia, disuse atrophy, and DMD (Duchenne muscular dystrophy); satellite cell activation and fusion; myotube diameter measurement in vitro; ActRIIB pathway pharmacology</li> <li><strong>Myostatin biology</strong> — competitive binding studies between follistatin-344 and anti-myostatin antibodies; dose-response relationships between myostatin concentration and follistatin neutralization efficiency; GDF-11 and activin A co-inhibition studies</li> <li><strong>BMP pathway research</strong> — osteoblast differentiation models, bone morphogenetic protein signaling in stem cell systems, adipogenic commitment in preadipocytes (BMP-4 driven), and neural specification models where BMP suppression determines neural vs. epidermal fate</li> <li><strong>Reproductive biology</strong> — folliculogenesis models, granulosa cell biology, FSH sensitivity regulation through activin A/follistatin balance, ovarian reserve research</li> <li><strong>Gene therapy and protein delivery research</strong> — follistatin-344 has been investigated in AAV-mediated muscle gene therapy contexts; follistatin fusion protein pharmacokinetics and tissue distribution studies</li> <li><strong>Cancer cachexia models</strong> — neutralization of tumor-derived activin A and GDF-11 contributing to muscle wasting; ActRIIB-driven cachexia models using follistatin-344 as a control arm</li> <li><strong>Cardiac muscle research</strong> — cardiomyocyte hypertrophy models and follistatin protective effects against activin A-mediated cardiac muscle atrophy or apoptosis</li> </ul>

<h2>Market Context</h2>

<p>Follistatin-344 is among the highest-value research peptides/proteins in terms of absolute listing price, reflecting the difficulty and cost of its synthesis. As a 344-amino-acid glycoprotein with multiple disulfide bonds and a glycosylation site, follistatin-344 is produced via recombinant expression systems (HEK293 or CHO cells preferred for correct glycosylation, E. coli for non-glycosylated variants) rather than chemical peptide synthesis, which adds manufacturing complexity and cost.</p>

<p>Peptides.SO tracks <strong>28 active supplier listings</strong> with pricing ranging from near $0 (sample/promo) to approximately $13,900 per listing, with a platform average near $934. Most research quantities are sold in 100 mcg or 1 mg vials. At high-quality supplier tier (99% purity, recombinant HEK293-expressed with correct glycosylation), pricing of $500–2,000 per 100 mcg is common. Lower-cost E. coli-expressed non-glycosylated variants exist but may have reduced biological activity in receptor-binding assays and should be validated independently.</p>

<p>Researchers should confirm whether the follistatin-344 they are procuring is glycosylated (from mammalian expression) or non-glycosylated (from E. coli), since glycosylation affects follistatin half-life, receptor binding kinetics, and activity in cell-based assays.</p>

<h2>Frequently Asked Questions</h2>

<p><strong>What is the difference between follistatin-288 and follistatin-344?</strong><br/> Both isoforms are produced from the same gene by alternative mRNA splicing. Follistatin-288 (288 amino acids) lacks the C-terminal 27-amino-acid heparin-binding extension present in follistatin-344. This extension causes follistatin-344 to bind heparan sulfate proteoglycans on cell surfaces and extracellular matrix, producing localized pericellular activity. Follistatin-288 circulates more freely in serum. In muscle research, the two isoforms produce similar myostatin neutralization but may differ in tissue distribution and duration of effect.</p>

<p><strong>Why does follistatin produce greater muscle mass increase than myostatin knockout?</strong><br/> Because myostatin is not the only ActRIIB ligand suppressing muscle mass. Activin A and GDF-11 also signal through ActRIIB to suppress muscle. Follistatin-344 binds and neutralizes all three ligands simultaneously, producing a broader derepression of muscle growth signaling than removing myostatin alone. The additive effect of multi-ligand neutralization is why follistatin overexpression approximately doubles the muscle mass increase seen in myostatin-null animals.</p>

<p><strong>Is recombinant follistatin-344 from E. coli biologically active?</strong><br/> Non-glycosylated follistatin-344 from E. coli can retain myostatin and activin A binding activity, but glycosylation contributes to protein stability, serum half-life, and binding kinetics. For cell-based or in vivo studies, mammalian-cell-expressed glycosylated follistatin-344 is preferred. E. coli-expressed material may be acceptable for certain in vitro binding assays where glycosylation is not critical for the readout.</p>

<p><strong>What concentration of follistatin-344 is used in in vitro muscle studies?</strong><br/> Published in vitro studies typically use 50–500 ng/mL follistatin-344 in the presence of exogenous myostatin or activin A (usually at 200–1000 ng/mL) to assess neutralization efficiency. In serum-free myoblast differentiation assays, endogenous activin A from FBS can be neutralized by follistatin-344 at concentrations of 100–300 ng/mL, producing enhanced myotube formation and myosin heavy chain expression.</p>

<h2>Cited Research</h2>

<ul> <li>Lee SJ, et al. "Regulation of muscle mass by follistatin and activins." <em>Mol Endocrinol.</em> 2010. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/20237061/" rel="noopener">20237061</a></li> <li>McPherron AC, Lee SJ. "Double muscling in cattle due to mutations in the myostatin gene." <em>Proc Natl Acad Sci USA.</em> 1997. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/9012850/" rel="noopener">9012850</a></li> <li>Lee SJ, et al. "Quadrupling muscle mass in mice by targeting TGF-β signaling pathways." <em>PLoS One.</em> 2007. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/17895881/" rel="noopener">17895881</a></li> <li>Rodino-Klapac LR, et al. "Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease." <em>Muscle Nerve.</em> 2009. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/19533616/" rel="noopener">19533616</a></li> <li>Nakashima M, et al. "The mechanism of bone morphogenetic protein action involves localized follistatin binding." <em>J Cell Biol.</em> 1997. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/9015291/" rel="noopener">9015291</a></li> </ul>

<p><em>For research purposes only. Follistatin-344 is not approved for human or veterinary therapeutic use, is not a drug or dietary supplement, and has not been evaluated by any regulatory authority for safety or efficacy in humans or animals outside controlled laboratory settings. All experimental use must comply with institutional biosafety and ethical guidelines.</em></p>